Navigation Links
Cardiome And Astellas Announce Regulatory Update
Date:1/21/2008

or the acute conversion of atrial fibrillation. Positive top-line results from two pivotal Phase 3 trials for vernakalant (iv), called ACT 1 and ACT 3, were released in December 2004 and September 2005. Cardiome's co-development partner Astellas Pharma US, Inc. submitted a New Drug Application for vernakalant (iv) in December 2006. Positive top-line results from an additional Phase 3 study evaluating patients with post-operative atrial arrhythmia, called ACT 2, were released in June 2007. An open-label safety study evaluating recent-onset AF patients, called ACT 4, has completed.

Vernakalant (oral) is being investigated as a chronic-use oral drug for the maintenance of normal heart rhythm following termination of AF. Cardiome announced positive results from a Phase 2a pilot study for vernakalant (oral) in September 2006. A Phase 2b study for vernakalant (oral) is ongoing.

In April 2007 Cardiome acquired exclusive worldwide rights for GED-aPC for all indications. Cardiome intends to initially develop GED-aPC in cardiogenic shock, a life-threatening form of acute circulatory failure due to cardiac dysfunction, which is a leading cause of death for patients hospitalized following a heart attack.

Cardiome is traded on the Toronto Stock Exchange (COM) and the NASDAQ National Market (CRME).

About Astellas

Astellas Pharma US, Inc., located in Deerfield, Illinois, is a U.S. affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The organization is committed to becoming a global category leader in focused areas by combining outstanding R&D and marketing capabilities.

In the US, Astellas markets products in the areas of Immunology, Urology, Anti-Infectives, Cardiovascular and Dermatology. For more information about Astellas Pharma US, Inc., please visit our website at '/>"/>

SOURCE Cardiome Pharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Cardiome to Hold Investor Update Call
2. Cardiome Updates Guidance
3. Cardiome Initiates Phase 1 Study for GED-aPC
4. Cardiome To Release Third Quarter Results
5. Cardiome to Present at CIBC Conference
6. Cardiome to Present at ThinkEquity Conference
7. Cardiome to Present at Bear Stearns Conference
8. Pharmacyclics Announces Conference Call to Discuss Second Quarter 2008 Financial Results
9. Cardica to Announce Fiscal 2008 Second Quarter Financial Results on Thursday, January 24, 2008
10. Lance Armstrong and 17th U.S. Surgeon General Carmona Announce National Call to Action in the War Against Cancer
11. Bradley Pharmaceuticals Announces Filing of Definitive Proxy Statement for Special Meeting of Stockholders to Approve Merger With Nycomed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... Today the members of the new ... National Alliance-National Ovarian Cancer Coalition Translational Research Dream ... on “DNA Repair Therapies for Ovarian Cancer,” building ... as a common weakness in ovarian cancer. Researchers ... of ovarian cancer by developing a web-based approach ...
(Date:4/20/2015)... 2015 Alcohol-related incidents have been recognized ... States for decades. These result in billions of ... property damage each year, while inflicting an enormous emotional ... their families and loved ones. Throughout the year and ... dedicated to raising awareness of alcohol addiction—its societal impact ...
(Date:4/20/2015)... Insuranceautoquote.info has released a new blog post ... online . , Affordable auto insurance quotes can ... should always compare online car insurance rates in their ... website: . http://insuranceautoquote.info , The process is ... in a few minutes and the search engine offers ...
(Date:4/20/2015)... 20, 2015 The 2015 Market ... is a professional and in-depth study on the ... Market with a focus on the Chinese ... amlodipine besylate market research are Pfizer, Novartis, Daiichi ... Lab., Par Pharma, Cadila Pharmaceuticals, Kangya Pharmaceuticals, Rui ...
(Date:4/20/2015)... Vancouver, British Columbia (PRWEB) April 20, 2015 ... developer of a hand-held Cannabix Marijuana Breathalyzer for law ... release of the first publicly available images of its ... of its Cannabix Marijuana Breathalyzer. Media files and video ... are available for online viewing at cannabixtechnologies.com . ...
Breaking Medicine News(10 mins):Health News:New Ovarian Cancer Dream Team to Research DNA Repair Therapies 2Health News:New Ovarian Cancer Dream Team to Research DNA Repair Therapies 3Health News:New Ovarian Cancer Dream Team to Research DNA Repair Therapies 4Health News:Drunk Driving Repeat Offenders: Suncoast Rehab Center Observes Alcohol Awareness Month by Advocating for Preventive Measures Against DUIs 2Health News:Drunk Driving Repeat Offenders: Suncoast Rehab Center Observes Alcohol Awareness Month by Advocating for Preventive Measures Against DUIs 3Health News:Drunk Driving Repeat Offenders: Suncoast Rehab Center Observes Alcohol Awareness Month by Advocating for Preventive Measures Against DUIs 4Health News:Affordable Auto Insurance Quotes Can Be Found Online, Fast and Easy 2Health News:Global Amlodipine Besylate Industry 2015-2020 Forecast Analysis Report 2Health News:Global Amlodipine Besylate Industry 2015-2020 Forecast Analysis Report 3Health News:Cannabix Technologies Inc. Releases New Images of Marijuana Breathalyzer Prototype 2Health News:Cannabix Technologies Inc. Releases New Images of Marijuana Breathalyzer Prototype 3Health News:Cannabix Technologies Inc. Releases New Images of Marijuana Breathalyzer Prototype 4
... , , ATLANTA, ... announced today the opening of its first Asia office in ... in the United States and abroad. The new office will support the current ... including some of the world,s largest organizations. , , ...
... 28 Cambrex Corporation (NYSE: CBM ) announced that second quarter 2009 financial results will ... The Company will host a conference call to discuss the second quarter 2009 financial results. , ... Second Quarter 2009 Earnings Conference Call, When: ... Dial-in: 1-888-634-4003 for U.S., ...
... hope vaccine will be available by fall or early winter ... trials of a vaccine against the new H1N1 swine flu ... and Prevention will convene a panel of experts Wednesday to ... Those recommendations will assume that a safe and effective vaccine ...
... , , ... CVS ) announced today that it has named Andrew J. Sussman, ... retail-based health clinic subsidiary, and as Senior Vice President/Associate Chief Medical ... will be responsible for all clinical services and daily operations for ...
... ... ... dollars on new digital hearing aids need look no further. AidRight Hearing ... nationwide network of more than 1,200 professionals and offers discounts on a wide variety of ...
... MAITLAND, Fla. , July 28 The STAR ... with plagiocephaly and other head shape abnormalities, opened a third location ... also has offices in the Baltimore and Dallas areas, and has ... referred to as a cranial helmets or headbands. , , ...
Cached Medicine News:Health News:North Highland Opens First Asia Office in Shanghai 2Health News:CDC Panel to Recommend Who Should Get Swine Flu Shot 2Health News:CDC Panel to Recommend Who Should Get Swine Flu Shot 3Health News:CVS Caremark Names Andrew J. Sussman, M.D., as President/Chief Operating Officer of MinuteClinic 2Health News:CVS Caremark Names Andrew J. Sussman, M.D., as President/Chief Operating Officer of MinuteClinic 3Health News:Hearing Aid Savings Galore 2Health News:New STAR Cranial Center of Excellence Offers Cutting-Edge Treatment to Central Florida Infants 2Health News:New STAR Cranial Center of Excellence Offers Cutting-Edge Treatment to Central Florida Infants 3Health News:New STAR Cranial Center of Excellence Offers Cutting-Edge Treatment to Central Florida Infants 4Health News:New STAR Cranial Center of Excellence Offers Cutting-Edge Treatment to Central Florida Infants 5
(Date:4/20/2015)... April 20, 2015 The global ... segments the concerned global with analysis and forecast of ... and is estimated to reach $4,918.7 million by 2019, ... Browse through the TOC of global orthopedic ... of the industry trends and segments, with help of ...
(Date:4/20/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/7t5xlp/us_proton_therapy ... Proton Therapy Outlook - Market Opportunities" report to ... Therapy Outlook: Market Opportunities by the author, ... almost 29 such centers by 2018, a number which ... will breach the Billion dollar mark to attain revenue ...
(Date:4/20/2015)... , April 20, 2015  In its ... healthcare markets, the FTC announced that Cardinal Health, ... illegally monopolized 25 local markets for the sale ... and clinics to pay inflated prices for these ... pay $26.8 million of ill-gotten gains and represents ...
Breaking Medicine Technology:Global Orthopedic Braces & Support System Market is Expected to Reach $4,918.7 Million by 2019, at a CAGR of 4.4% from 2014 to 2019 2Global Orthopedic Braces & Support System Market is Expected to Reach $4,918.7 Million by 2019, at a CAGR of 4.4% from 2014 to 2019 3United States Proton Therapy Outlook to 2018 - Market Opportunities for the $1.19 Billion Market Featuring IBA, Hitachi, Mevion Medical Systems & Varian 2United States Proton Therapy Outlook to 2018 - Market Opportunities for the $1.19 Billion Market Featuring IBA, Hitachi, Mevion Medical Systems & Varian 3Cardinal Health Agrees to Pay $26.8 Million to Settle Charges It Monopolized 25 Markets for the Sale of Radiopharmaceuticals to Hospitals and Clinics, says FTC 2Cardinal Health Agrees to Pay $26.8 Million to Settle Charges It Monopolized 25 Markets for the Sale of Radiopharmaceuticals to Hospitals and Clinics, says FTC 3Cardinal Health Agrees to Pay $26.8 Million to Settle Charges It Monopolized 25 Markets for the Sale of Radiopharmaceuticals to Hospitals and Clinics, says FTC 4Cardinal Health Agrees to Pay $26.8 Million to Settle Charges It Monopolized 25 Markets for the Sale of Radiopharmaceuticals to Hospitals and Clinics, says FTC 5
... ... ... ... ...
... ... ... ... ...
Cached Medicine Technology:Data Show Valortim(R) Anthrax Anti-Toxin May Augment Immune System's Ability to Destroy Anthrax Bacteria 2Data Show Valortim(R) Anthrax Anti-Toxin May Augment Immune System's Ability to Destroy Anthrax Bacteria 3Data Show Valortim(R) Anthrax Anti-Toxin May Augment Immune System's Ability to Destroy Anthrax Bacteria 4Data Show Valortim(R) Anthrax Anti-Toxin May Augment Immune System's Ability to Destroy Anthrax Bacteria 5Data Show Valortim(R) Anthrax Anti-Toxin May Augment Immune System's Ability to Destroy Anthrax Bacteria 6Data Show Valortim(R) Anthrax Anti-Toxin May Augment Immune System's Ability to Destroy Anthrax Bacteria 7Data Show Valortim(R) Anthrax Anti-Toxin May Augment Immune System's Ability to Destroy Anthrax Bacteria 8WuXi PharmaTech Passes EMEA Inspection of Its GMP Manufacturing and Analytical Testing Facilities in Shanghai 2WuXi PharmaTech Passes EMEA Inspection of Its GMP Manufacturing and Analytical Testing Facilities in Shanghai 3WuXi PharmaTech Passes EMEA Inspection of Its GMP Manufacturing and Analytical Testing Facilities in Shanghai 4WuXi PharmaTech Passes EMEA Inspection of Its GMP Manufacturing and Analytical Testing Facilities in Shanghai 5WuXi PharmaTech Passes EMEA Inspection of Its GMP Manufacturing and Analytical Testing Facilities in Shanghai 6
... The Strep B OIA test ... streptococcal antigen directly from cervical or ... If culture results are unknown at ... STREP B OIA offers physicians additional ...
... delivers excellent sensitivity and specificity for the diagnosis ... test that provides an answer in 6 minutes. ... provide improved patient care with a test that ... out what value we bring to your daily ...
... and nerve block procedures, Cadwells disposable ... a precisely machined Trocar (beveled) tip ... 61-cm (24-in) lead wire. Needle is ... use only. A starter kit includes ...
Shielding's new Surgical Drop Away / Flex Back Apron offers top of the shoulder velcro flaps for an adjustable fit. Features elastic back panels for added comfort and support. For quick removal apron...
Medicine Products: